[
    [
        {
            "time": "2021-10-22",
            "original_text": "NINETE ONE UK LIMITED 10月22日减持2.27万股泰格医药股份，涉资340.81万港元 减持股份",
            "features": {
                "keywords": [
                    "减持",
                    "泰格医药",
                    "NINETE ONE UK LIMITED"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "NINETE ONE UK LIMITED 10月22日减持2.27万股泰格医药股份，涉资340.81万港元 减持股份",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-21",
            "original_text": "NINETE ONE UK LIMITED 10月21日增持2.03万股泰格医药股份，涉资305.05万港元",
            "features": {
                "keywords": [
                    "增持",
                    "泰格医药",
                    "NINETE ONE UK LIMITED"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "NINETE ONE UK LIMITED 10月21日增持2.03万股泰格医药股份，涉资305.05万港元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "泰格医药前三季度净利18亿元同比增35% 股价涨6.7%",
            "features": {
                "keywords": [
                    "净利",
                    "同比增长",
                    "股价上涨",
                    "泰格医药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药前三季度净利18亿元同比增35% 股价涨6.7%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-22",
            "original_text": "泰格医药：曹晓春女士于10月22日将75万股公司股份解除质押",
            "features": {
                "keywords": [
                    "解除质押",
                    "泰格医药",
                    "曹晓春"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药：曹晓春女士于10月22日将75万股公司股份解除质押",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-Q4",
            "original_text": "泰格医药：公司四季度营收情况一般会高于其余几个季度",
            "features": {
                "keywords": [
                    "四季度",
                    "营收",
                    "泰格医药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药：公司四季度营收情况一般会高于其余几个季度",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10",
            "original_text": "浙商证券维持泰格医药买入评级，泰格医药2021Q3业绩点评：景气延续，阶段跃迁，持续推荐！",
            "features": {
                "keywords": [
                    "买入评级",
                    "浙商证券",
                    "泰格医药",
                    "业绩点评"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "浙商证券维持泰格医药买入评级，泰格医药2021Q3业绩点评：景气延续，阶段跃迁，持续推荐！",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10",
            "original_text": "信达证券发布泰格医药研报，公司点评报告：三季报业绩超预期，公司业务加速恢复",
            "features": {
                "keywords": [
                    "研报",
                    "信达证券",
                    "泰格医药",
                    "三季报",
                    "业绩超预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "信达证券发布泰格医药研报，公司点评报告：三季报业绩超预期，公司业务加速恢复",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10",
            "original_text": "西部证券维持泰格医药买入评级，2021年三季报点评：主营业务加速恢复，季度业绩创新高",
            "features": {
                "keywords": [
                    "买入评级",
                    "西部证券",
                    "泰格医药",
                    "三季报",
                    "主营业务"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西部证券维持泰格医药买入评级，2021年三季报点评：主营业务加速恢复，季度业绩创新高",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10",
            "original_text": "光大证券：维持泰格医药(300347.SZ)“买入”评级 Q3主业继续提速 长期业绩发展向好",
            "features": {
                "keywords": [
                    "买入评级",
                    "光大证券",
                    "泰格医药",
                    "Q3",
                    "主业提速"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "光大证券：维持泰格医药(300347.SZ)“买入”评级 Q3主业继续提速 长期业绩发展向好",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10",
            "original_text": "西南证券维持泰格医药持有评级：业绩增长超预期，国际化值得期待",
            "features": {
                "keywords": [
                    "持有评级",
                    "西南证券",
                    "泰格医药",
                    "业绩增长",
                    "国际化"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券维持泰格医药持有评级：业绩增长超预期，国际化值得期待",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]